Video Transcript: Ocular Therapeutix™ ELUTYX™ Technology

Animation of ELUTYX. Engineered to create biocompatible therapeutics designed to provide sustained and localized drug delivery.^1-5

References: 1. Sawhney AS, et al., Inventors, Incept, LLC, Assignee. Drug delivery through hydrogel plugs. US Patent 8,409,606 B2. April 2, 2013. 2. Driscoll A, Blizzard C, Toxicity and Pharmacokinetics of Sustained-Release Dexamethasone in Beagle Dogs. Adv Ther. 2016;33(1):58-67. 3. Lee A, Blair HA. Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation. Drugs. 2020;80(11):1101-1108. 4. Boyer DS, et al. Evaluating Safety, Tolerability and Biological Activity of OTX-TKI, a Hydrogel-Based, Sustained-Release Intravitreal Axitinib Implant, in Subjects with Neovascular Age-Related Macular Degeneration. Presented at the American Academy of Ophthalmology Annual Meeting; Virtual; November 13-15, 2020. 5. Goldstein MH, Goldberg D, Walters TR, Vantipalli S, Braun E, Metzinger JL. Evaluating Safety, Tolerability and Efficacy of an Intracameral Hydrogel-Based Travoprost Implant in Subjects with Glaucoma – Phase 1 Trial. Invest Ophthalmol Vis Sci. 2020;61 (7):4266.

Animation of ELUTYX eluting (releasing) drug. Animation of eye showing placement of intracanalicular ELUTYX, intracameral ELUTYX, and intravitreal ELUTYX. Animation of hydrogel matrix that makes up ELUTYX showing PEG (Polyethylene glycol), Trilysine, and Hydrolyzable Linkages. ELUTYX™ technology does not contain PEGylated components. Animation of hydrogel matrix showing entrapment of drug particle. ELUTYX™: Entraps drug particles. ELUTYX™: Hydrates with water and drug particles begin to dissolve and diffuse into surrounding tissues.¹

Reference: 1. Blizzard C, Desai A, Driscoll A. Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs. J Ocul Pharmacol Ther. 2016;32 (9):595-600.

Expanded view of entrapped drug particles in hydrogel matrix. ELUTYX™: Hydrates with water and drug particles begin to dissolve and diffuse into surrounding tissues.¹

Reference: 1. Blizzard C, Desai A, Driscoll A. Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs. J Ocul Pharmacol Ther. 2016;32 (9):595-600.

Animation of ELUTYX biodegrading. ELUTYX™: Biodegrades and is cleared from the body following completion of drug delivery.¹

Reference: 1. Lee A, Blair HA. Dexamethasone Intracanalicular Insert: A Review in Treating Post-Surgical Ocular Pain and Inflammation. Drugs. 2020;80 (11):1101-1108.

Animation of ELUTYX eluting over days and months. Days¹; ELUTYX™ can be formulated for sustained delivery; Months.²

References: 1. Pehlivaner M, et al. Reduced Ocular Inflammation and Improved GFP Expression in Rabbits with Controlled Release of AAV from Degradable Hydrogel Implants. Presented at the American Society of Gene & Cell Therapy (ASGCT): May 19, 2022; Washington DC. 2. Moshfeghi AA, et al. U.S. Phase 1 Study of Intravitreal Axitinib Implant (OTX-TKI) for Neovascular Age related Macular Degeneration. Invest Ophthalmol Vis Sci. 2023;64(8):936.

Animation of ELUTYX with small molecules and large proteins entrapped. ELUTYX™ can be used to deliver both small molecules and large proteins at both small and large molecular weights.^1-4

References: 1. Boyer DS, et al. Evaluating Safety, Tolerability and Biological Activity of OTX-TKI, a Hydrogel-Based, Sustained-Release Intravitreal Axitinib Implant, in Subjects with Neovascular Age-Related Macular Degeneration. Presented at the American Academy of Ophthalmology Annual Meeting; Virtual; November 13-15, 2020. 2. Goldstein MH, Goldberg D, Walters TR, Vantipalli S, Braun E, Metzinger JL. Evaluating Safety, Tolerability and Efficacy of an Intracameral Hydrogel-Based Travoprost Implant in Subjects with Glaucoma – Phase 1 Trial. Invest Ophthalmol Vis Sci. 2020;61 (7):4266. 3. Blizzard C, Desai A, Driscoll A. Pharmacokinetic Studies of Sustained-Release Depot of Dexamethasone in Beagle Dogs. J Ocul Pharmacol Ther. 2016;32 (9):595-600. 4. Elhayek RF, Jarrett PK, Sawhney A, et al. Pharmacokinetics of Bevacizumab Sustained Release. from Intravitreal Hydrogel Depots in a Rabbit Model Compared to a single Avastin Dose. Invest Ophthalmol Vis Sci. 2015;56 (7):1522.

Outro with animation of hydrogel matrix. For more information on the ELUTYX™ Technology visit ocutx.com.